LCI completes acquisition of Pfizer’s manufacturing facility

KARACHI: Lucky Core Industries (LCI) has announced the completion of Pfizer Pakistan’s manufacturing facility in Karachi.The company in a statement to the Pakistan Stock Exchange (PSX) on Monday said that it had completed the acquisition of Pfizer Pakistan Limited’s manufacturing facility at B2 SITE Karachi along with the acquisition of product and registrations of: Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Cortex-D and Mycitracin and trademarks associated with these mentioned pharmaceutical products (either through an outright assignment of trademarks or a perpetual license to use the relevant trademarks) from relevant Pfizer group entities.

“We are pleased to inform you that the aforementioned asset acquisition has successfully been completed on September 6, 2024 in accordance with the asset purchase agreements entered into between the parties,” read the statement.